DGNews
New Clinical Practice Guideline on Alcoholic Liver Disease Published
BARCELONA, Spain -- April 19, 2012 -- The European Association for the Study of the Liver (EASL) today announced the publication of a new clinical practice guideline in the area of alcoholic liver disease.
Alcoholic liver disease is the leading cause of liver disease in eastern and western Europe, yet there has been limited research investment in this area and the development of clinical practice guidelines is therefore both timely and necessary.
The EASL Clinical Practice Guidelines on Alcoholic Liver Disease, build on the issues raised at the Monothematic Conference on Alcoholic Liver Disease (Athens 2010) and have been developed with 3 main aims: to (1) provide physicians with clinical recommendations; (2) to emphasise the fact that alcohol can cause several liver diseases, all of which may coexist in the same patient; and (3) to identify areas of interest for future research, including clinical trials
The guidelines cover the burden of alcoholic liver disease, management of alcohol abuse and dependence, pathogenesis, risk factors for disease progression, diagnosis, alcoholic hepatitis, alcoholic cirrhosis, and liver transplantation.
The guidelines will be published in August 2012 issue of the Journal of Hepatology.
In addition, EASL has also published a revised clinical practice guideline on the management of chronic hepatitis B virus (HBV). This update incorporates changes to a number of areas including: new indications for liver biopsy and the treatment of HBeAg-negative patients; the recommendation for less frequent HBV DNA testing under entecavir or tenofovir; and the provision of more detailed recommendations for specific sub-groups, particularly HBV and pregnancy and HBV and immunosuppression.
The complete practice guideline can be found here: http://www.easl.eu/_clinical-practice-guideline
SOURCE: European Association for the Study of the Liver
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment